BRPI0911490A2 - derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5) - Google Patents

derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5)

Info

Publication number
BRPI0911490A2
BRPI0911490A2 BRPI0911490A BRPI0911490A BRPI0911490A2 BR PI0911490 A2 BRPI0911490 A2 BR PI0911490A2 BR PI0911490 A BRPI0911490 A BR PI0911490A BR PI0911490 A BRPI0911490 A BR PI0911490A BR PI0911490 A2 BRPI0911490 A2 BR PI0911490A2
Authority
BR
Brazil
Prior art keywords
alk4
alk5
kinase inhibitors
receptor kinase
activin receptor
Prior art date
Application number
BRPI0911490A
Other languages
English (en)
Portuguese (pt)
Inventor
Catherine Leblanc
Cathy Ritchie
Duncan Shaw
Nikolaus Johannes Stiefl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0911490A2 publication Critical patent/BRPI0911490A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0911490A 2008-04-29 2009-04-27 derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5) BRPI0911490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155405 2008-04-29
PCT/EP2009/055066 WO2009133070A1 (en) 2008-04-29 2009-04-27 Imidazo-pyridine derivatives as activin-like receptor kinase (alk4 or alk5) inhibitors

Publications (1)

Publication Number Publication Date
BRPI0911490A2 true BRPI0911490A2 (pt) 2016-01-05

Family

ID=40043988

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911490A BRPI0911490A2 (pt) 2008-04-29 2009-04-27 derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5)

Country Status (14)

Country Link
US (1) US9079897B2 (https=)
EP (1) EP2307402B1 (https=)
JP (1) JP5507543B2 (https=)
KR (1) KR20100130226A (https=)
CN (1) CN102015691B (https=)
AU (1) AU2009242145B2 (https=)
BR (1) BRPI0911490A2 (https=)
CA (1) CA2722131A1 (https=)
EA (1) EA201001687A1 (https=)
ES (1) ES2399175T3 (https=)
MX (1) MX2010011867A (https=)
PL (1) PL2307402T3 (https=)
PT (1) PT2307402E (https=)
WO (1) WO2009133070A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012018954A2 (pt) 2010-02-05 2016-04-12 Merck Patent Gmbh derivados de hetaril-[1,8]naftiridina
SG183233A1 (en) 2010-02-22 2012-09-27 Merck Patent Gmbh Hetarylaminonaphthyridines
US9073918B2 (en) 2010-05-20 2015-07-07 Takeda Pharmaceutical Company Limited Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
WO2012064043A2 (ko) 2010-11-08 2012-05-18 에스케이케미칼 주식회사 폴리유산 수지, 이의 제조 방법 및 이를 포함하는 포장용 필름
AU2012240656A1 (en) * 2011-04-05 2013-10-24 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
JP2016510764A (ja) 2013-03-07 2016-04-11 カリフィア バイオ, インク.Califia Bio, Inc. 混合系キナーゼ阻害剤および治療法
US10179777B2 (en) 2015-04-16 2019-01-15 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
US10508082B2 (en) * 2015-09-23 2019-12-17 Dana-Farber Cancer Institute, Inc. Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK
RU2642456C2 (ru) * 2016-06-29 2018-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный университет им. П.Г. Демидова" Способ получения N-арилзамещенных 3H-имидазо[4,5-b]пиридинов
JP7007359B2 (ja) 2016-07-29 2022-01-24 シャンハイ インリ ファーマシューティカル カンパニー リミティド 窒素含有芳香族複素環式化合物、その製造方法、薬物組成物および使用
CN106831770A (zh) * 2017-03-13 2017-06-13 牡丹江医学院 一种药物组合物及其用于治疗肝硬化的用途
CN110066277B (zh) 2018-01-24 2021-07-23 上海璎黎药业有限公司 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
US20200247812A1 (en) * 2018-07-10 2020-08-06 Integral Biosciences Private Limited Heterocyclic compounds and methods of use
MX2021003904A (es) * 2018-10-05 2021-10-26 Annapurna Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
JP2023509760A (ja) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド Ａｌｋ５阻害剤複合体およびその使用
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
EP4182308B1 (en) 2020-07-15 2024-09-04 Chiesi Farmaceutici S.p.A. Pyridazinyl amino derivatives as alk5 inhibitors
EP4182323B1 (en) 2020-07-15 2024-04-24 Chiesi Farmaceutici S.p.A. Pyrido oxazine amino derivatives as alk5 inhibitors
ES2982017T3 (es) 2020-07-15 2024-10-14 Chiesi Farm Spa Derivados de pirido-oxazina como inhibidores de ALK5
EP4267584A1 (en) 2020-12-23 2023-11-01 Chiesi Farmaceutici S.p.A. Pyrido oxazine derivatives as alk5 inhibitors
US20250011299A1 (en) 2021-09-21 2025-01-09 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
EP4514802A1 (en) 2022-04-27 2025-03-05 Chiesi Farmaceutici S.p.A. Imidazole derivatives as alk5 inhibitors
CN121712526A (zh) 2023-06-13 2026-03-20 辛瑟斯治疗股份有限公司 抗cd5抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
GB9921150D0 (en) * 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB0217783D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
WO2005023246A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
PL2044056T3 (pl) * 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
JP2010508315A (ja) * 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物

Also Published As

Publication number Publication date
JP2011518856A (ja) 2011-06-30
US20110060004A1 (en) 2011-03-10
JP5507543B2 (ja) 2014-05-28
CA2722131A1 (en) 2009-11-05
KR20100130226A (ko) 2010-12-10
AU2009242145A1 (en) 2009-11-05
PT2307402E (pt) 2013-02-15
ES2399175T3 (es) 2013-03-26
MX2010011867A (es) 2010-11-26
US9079897B2 (en) 2015-07-14
EP2307402B1 (en) 2012-11-07
CN102015691A (zh) 2011-04-13
EA201001687A1 (ru) 2011-06-30
WO2009133070A1 (en) 2009-11-05
AU2009242145B2 (en) 2012-07-05
EP2307402A1 (en) 2011-04-13
CN102015691B (zh) 2014-01-08
PL2307402T3 (pl) 2013-05-31

Similar Documents

Publication Publication Date Title
BRPI0911490A2 (pt) derivados de imidazo-piridina como inibidores de cinase receptora tipo activina (alk4 ou alk5)
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
IL209864A0 (en) Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
BR112012029405A2 (pt) compostos macrocíclicos como inibidores de trk quinase
ES2598358T8 (es) Derivados de quinolina como inhibidores de PI3K quinasa
BRPI1005327A2 (pt) derivados de triazolopiridina como inibidores de p38 map quinase
BR112013014854A8 (pt) compostos de n-(1h-indazol-4-il)imidazo [1,2-a] piridina-3-carboxamida substituídos como inibidores de tirosina quinase de receptor tipo iii
ZA201204138B (en) Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
IL200804A0 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
PT2947081T (pt) Imidazois substituídos por 2-piridil como inibidores de alk5 e/ou alk4 terapêuticos
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
IL218032A0 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
CR10849A (es) Derivados de benzamida como agonistas del receptor ep4
EP2498607A4 (en) Kinase Inhibitors
EP2493313A4 (en) Kinase Inhibitors
BRPI0910832A2 (pt) Derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk)
BRPI0910439A2 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk)
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0906625A2 (pt) Derivados de tio-2-amino-quinolina-6-substituída úteis como inibidores da beta-secretase (bace)
PL2419427T3 (pl) Dwupierścieniowe pochodne heterocykliczne związków jako kinazy tyrozynowe FGFR do terapeutycznego stosowania
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
EP2558099A4 (en) Kinase inhibitors
BR112012008108A2 (pt) derivados de xantina substituídos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.